Featured News

2023 promises to be a year full of robust research, advocacy, and education efforts on behalf of our patient community.

The American College of Gastroenterology has updated its guidelines for the diagnosis and management of celiac disease, bringing current the recommendations outlined in 2013.

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.

The Celiac Disease Foundation is pleased to announce it will provide patient recruitment and eligibility screening for Anokion’s phase 1b/2 clinical trial for KAN-101.

On October 13, 2022 the Celiac Disease Foundation hosted the Ask-the-FDA Educational Webinar with representatives from the U.S. Food and Drug Administration and Coeliac UK.

The Celiac Disease Foundation announces its newest appointee, William Thurston, to its Board of Directors.

The PROACTIVE Celiac Study is a phase 2 clinical trial testing the safety and effects of the investigational medication PRV-015.

Consider joining the LILY Study, a phase 1 clinical trial for people with celiac disease investigating DONQ52, a new potential celiac disease treatment.

iCureCeliac® is the Foundation’s patient-powered tool that is the single best resource for celiac disease researchers around the world helping to accelerate the search for treatments and a cure.

We are pleased to introduce a new 7-Day Mediterranean Diet Meal Plan, developed by Janelle Smith, Registered Dietitian at UCLA.